Leo O'Connor[email protected]Business InsightsWeek in Review: Labcorp liquid biopsy | Deep sequencing | Heart disease markers and diabetesLabcorp has launched a liquid biopsy test to enable targeted therapy selection for patients with advanced or metastatic solid tumors.June 1, 2023Policy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsThe FDA should use its authority to develop laboratory-developed test regulations if Congress does not pass legislation requiring it, said the Center for Science in the Public Interest and other organizations.June 1, 2023Business InsightsIllumina CEO remains on the board, chairman is voted outActivist investor Carl Icahn, in a proxy fight, had urged the shareholders to remove the chairman and CEO from the board.May 26, 2023Business InsightsWeek in Review: Long COVID’s symptoms | Protection against Omicron | Reducing non-respiratory symptom riskWorking with the NIH RECOVER Initiative, researchers at Mass General Brigham have defined signature symptoms of long COVID in a prospective cohort study.May 25, 2023Molecular DiagnosticsDomus Diagnostics gets $2.4M NIH grant to develop at-home molecular testThe award, granted as part of the NIH Rapid Acceleration of Diagnostics (RADx) Tech program, will support accelerated validation and scaling of a testing platform to prepare it for a clinical trial.May 24, 2023Financial ResultsAgilent Technologies fiscal Q2 revenues rise 7%; firm trims full-year estimatesDiagnostics and Genomics Group revenues were $362 million, up 1% year-over-year compared to $358 million.May 24, 2023ImmunoassaysBeckman Coulter analyzer developed 'from the ground up' to address IVD industry constraintsAt a time of scarce resources, the system requires no daily maintenance and only 10 minutes weekly and monthly maintenance, said Dr. Pamela Christudoss of Christian Medical College, who evaluated the analyzer prior to its broad launch last week.May 23, 2023510(k)Hologic obtains FDA clearance for multiplex SARS-CoV-2/Flu A/Flu B/RSV assayThe Panther Fusion SARS-CoV-2/Flu A/B/RSV assay runs on the fully automated, high-throughput Panther Fusion system, which provides initial results in approximately three hours and can process more than 1,000 tests in 24 hours.May 19, 2023Business InsightsWeek in Review: Quest on detecting dementia | Roche routine mass-spec test | A Labcorp acquisitionRoche Diagnostics will showcase technologies for lab automation, the serum work area, and molecular and point-of-care solutions at an industry event; it is also unveiling a prototype for the Cobas Mass Spec system.May 18, 2023Business InsightsWeek in Review: Public Health Emergency ends | BioMérieux nabs FDA CLIA waiver | QuidelOrtho granted de novo requestThe FDA this past week continued to grant regulatory approvals for tests associated with COVID-19 that lay outside the scope of the emergency use authorization pathway.May 11, 2023Previous PagePage 2 of 17Next PageTop StoriesValidationImmunovia announces positive results for next-gen pancreatic cancer testDiagnostics company Immunovia announced positive results for the newest generation of its pancreatic cancer test from a model-development study, announcing that the test achieved both its primary and secondary endpoints.CollaborationVertex to pay $25M upfront to scale cell manufacturing technologyFinancial ResultsBristol Myers Squibb to reduce workforce in restructuring planLawsuitU.K. Patents Court rules Bio-Techne patents invalid in infringement lawsuitSponsor ContentVisit our Molecular Diagnostics Community
